NEW YORK—Marcia Kean, who sold her firm Feinstein Kean Healthcare to Ogilvy Public Relations Worldwide three years ago, has returned to the healthcare communications and business consulting firm as chief executive officer.
She rejoins Feinstein Kean from Lexington-based Ardais Corporation, a privately-held clinical genomics firm, where she led the initial commercialization of that company’s drug discovery products and services.
“We asked Marcia back as part of Ogilvy’s strong commitment to Feinstein Kean Healthcare and its unique positioning as a senior strategic partner within the healthcare sector,” said Ogilvy chief executive Marcia Silverman. “Marcia returns to the firm as a proven leader with biotech and pharmaceutical industry knowledge, a superb reputation with clients, and a strong track record for attracting, growing and retaining talented staff with diverse skill sets.”
Ogilvy PR Worldwide purchased Feinstein Kean in November 1999.
“The biotech industry is maturing, with more companies at all stages of development having to confront a complex array of financing, public policy and commercial issues,” says Kean, who previously served as managing director of the FKH corporate communications practice for 12 years. “Feinstein Kean has the unique depth of experience and breadth of capabilities in the biotech and pharmaceutical arenas to address the strategic business and communications issues for companies from start-up through commercialization.”
Before Feinstein Kean, Kean served simultaneously as vice president, corporate communications of Damon Corporation and its subsidiary Damon Biotech, one of the first biotech companies in New England. Previously she held the position of manager, financial relations for SmithKline Corporation.